Combined percutaneous auricular vagus nerve stimulation and ultrasound-guided phrenic nerve block for persistent hiccups: A case report. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42470050
Investigate the use of phrenic nerve block and auricular vagus nerve stimulation for treating persistent hiccups, noting potential efficacy but requiring further research.
Combined phrenic nerve block and auricular vagus nerve stimulation resolved persistent hiccups in a patient with chronic hepatitis B, hypertension, type 2 diabetes, and prior pulmonary tuberculosis. Larger studies are needed.
The Use of FGF21 Analogues in MASH and MASH Cirrhosis - Metabolic Master Regulators or Liver-Specific Mechanisms? . - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42435974
FGF21 analogues are studied for effects on liver fibrosis and cirrhosis, with early trials showing histological improvements. Phase 3 trials aim to assess liver-related outcomes.
FGF21 analogues, including efruxifermin, pegozafermin, and efimosfermin, show histological improvements in fibrotic MASH and regression in cirrhosis in phase 2 trials.
Gut microbiota-derived extracellular vesicles: bridging microbial-host crosstalk in metabolic disorders. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42399985
Discover how gut microbiota-derived extracellular vesicles affect metabolic disorders like obesity and T2DM, offering new diagnostic and therapeutic possibilities.
Gut microbiota-derived extracellular vesicles influence obesity, T2DM, MASLD, atherosclerosis, and hypertension, with diagnostic and therapeutic potential in primary care.
Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41480657
Research highlights significant age (OR: 0.22-0.56) and sex disparities in SGLT2 inhibitor prescriptions for T2DM patients, unaffected by frailty, indicating a need for more...
SGLT2 inhibitor prescriptions are lower in older adults with T2DM, with significant age (OR: 0.22-0.56) and sex disparities unaffected by frailty.
Rationale and design of a parallel randomised trial of a plant-based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt-based weight loss InteRvention (REPAIR) trial. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41623136
Explore the REPAIR trial's 52-week plant-based intervention for type 2 diabetes remission, aiming for ≥15% weight loss in a diverse population.
The REPAIR trial evaluates a 52-week plant-based lifestyle intervention for diabetes remission, targeting ≥15% weight loss and behavior change.